Novel oral anticoagulants in development: Dabigatran, rivaroxaban, and apixaban

Keyphrases

• Clinical Profile 100%
• Novel Oral Anticoagulants 100%
• Dabigatran 100%
• Apixaban 100%
• Rivaroxaban 100%
• New Agents 50%
• Pharmacologic 50%
• Small Molecules 50%
• Anticoagulants 50%
• Deep Vein Thrombosis 50%
• Pulmonary Embolism 50%
• Underuse 50%
• Warfarin 50%
• Unfractionated Heparin 50%
• Routine Clinical Practice 50%
• Traditional Therapy 50%
• Long-term Management 50%
• Anticoagulation Treatment 50%
• Oral Formulation 50%
• Factor Xa Inhibitors 50%
• Coagulation Monitoring 50%
• Novel Anticoagulants 50%
• Duration of Anticoagulation 50%
• Thromboembolism Prevention 50%
• Thrombin Inhibitor 50%
• Venous Thromboembolic Disease 50%
• Oral Vitamin K Antagonists 50%
• Thrombosis Treatment 50%

Pharmacology, Toxicology and Pharmaceutical Science

• Anticoagulant Agent 100%
• Dabigatran 100%
• Rivaroxaban 100%
• Apixaban 100%
• Thromboembolism 33%
• Heparin 33%
• Deep Vein Thrombosis 33%
• Morbidity 33%
• Thrombosis 33%
• Venous Thromboembolism 33%
• Lung Embolism 33%
• Warfarin 33%
• Vitamin K Group 33%
• Blood Clotting Factor 10a Inhibitor 33%
• EC 3.4.21.5 (Thrombin) Inhibitor 33%